In:
Cancer, Wiley, Vol. 123, No. 1 ( 2017-01), p. 90-97
Kurzfassung:
Dasatinib demonstrates no significant antisarcoma activity in patients with epithelioid sarcoma or solitary fibrous tumor. Patients with alveolar soft part sarcoma have prolonged disease progression–free and overall survival, but this is not necessarily caused by dasatinib. A small minority of patients with chondrosarcoma or chordoma experience an objective tumor response or prolonged stabilization of disease, and this suggests that dasatinib treatment should be further evaluated for these sarcoma subtypes. See also pages 20‐4.
Materialart:
Online-Ressource
ISSN:
0008-543X
,
1097-0142
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2017
ZDB Id:
1479932-7
ZDB Id:
2599218-1
ZDB Id:
2594979-2
ZDB Id:
1429-1
